Application release active antibodies in complex treatment of patients with benign prostatic hyperplasia

Abstract

An assessment of the clinical effectiveness and safety without the danger of drugs Afala and Impaza in the complex treatment of patients with benign prostatic hyperplasia (BPH) and erectile dysfunction. The study involved 132 men aged 50 to 70 years. Depending on the treatment of BPH patients were divided into 4 groups: group 1 patients (n = 35) received only conservative therapy, patients in group 2 (n = 30) was performed photoselective laser vaporization (PLV) BPH. 3 groups of patients (n = 35) – transurethral resection (TUR) of BPH patients to 4 groups (n = 32) performed a combination of PLV and TUR BPH. Patients all groups received the drug Afala and Impaza. Following the comprehensive treatment of prostate volume reduction of 75 %, 90 % of patients showed an increase in urinary flow rate 15–17 ml/s, and improvement in QoL noted IPSS 89 %, normalization of sexual function – 78 % of patients